BioPharma Dive ٢ يونيو ٢٠٢٦ Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial
BioPharma Dive ٢ يونيو ٢٠٢٦ Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug
BioPharma Dive ٢ يونيو ٢٠٢٦ ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer
BioPharma Dive ٣١ مايو ٢٠٢٦ ‘Unprecedented’ Revolution data point to paradigm shift in pancreatic cancer